MH3D
MH3D Inc. is a medical device company that builds and sells the Alpha-SPECT Mini, the world's first CZT-based preclinical SPECT imaging system for direct in vivo imaging of alpha-emitting radiopharmaceuticals, sold primarily to contract research organizations and academic medical centers.
- Company typePrivate
- Founded2023
- HeadquartersCommerce Township, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MH3D does
MH3D Inc. is a privately held medical device company founded in 2023 and headquartered in Ann Arbor, Michigan, that develops next-generation preclinical SPECT (Single-Photon Emission Computed Tomography) imaging systems for nuclear medicine research. Its flagship and sole commercial product is the Alpha-SPECT™ Mini, the world's first CZT (Cadmium Zinc Telluride) semiconductor detector-based preclinical SPECT system. The platform delivers approximately 2.5% energy resolution at 140 keV, a fully stationary detector geometry with a dual-FOV micro-scanning aperture, multi-isotope imaging (including direct imaging of alpha-emitting radiopharmaceuticals such as Actinium-225), and supports up to four mice per scan for biodistribution, dosimetry, PK/PD, and longitudinal theranostics studies. Underlying IP traces to over two decades of nuclear imaging detector research at the University of Michigan (Dr. Zhong He, 3D-readout technique) and the University of Illinois at Urbana-Champaign (Dr. Ling-Jian Meng), with commercialization led by CEO Xiaopei Huang.
MH3D monetizes the Alpha-SPECT Mini primarily through capital equipment sales of high-priced preclinical imaging systems to contract research organizations (CROs) and academic medical centers. Go-to-market combines direct enterprise field sales, a distribution partnership with Scintica Instrumentation, and event-driven demand generation at WMIC, SNMMI, and the Preclinical Imaging Consortium. The company sells through quote-based enterprise pricing with multi-year contract terms, supplemented by an exclusive service partnership with Perceptive Discovery that launched the α-Sight™ imaging service in April 2026, converting MH3D's installed hardware into a recurring outsourced imaging offering for pharma/biotech sponsors. Customers disclosed to date are Johns Hopkins University School of Medicine, Perceptive Discovery, and Minerva Imaging (Europe). The firm had 1–10 employees as of latest disclosure and closed a single funding round of approximately $3.31M in January 2025.
MH3D firmographics
Firmographics- Name
- MH3D
- Legal name
- MH3D Inc.
- Website
- https://mh3dinc.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- MH3D Inc. is a medical device company that builds and sells the Alpha-SPECT Mini, the world's first CZT-based preclinical SPECT imaging system for direct in vivo imaging of alpha-emitting radiopharmaceuticals, sold primarily to contract research organizations and academic medical centers.
- Ownership category
- akta.pro rank
MH3D industry classification
Industry- Product category
- Preclinical Nuclear Imaging Systems
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Nuclear Medicine & Molecular Imaging (SPECT/PET) (HLAHABAE)
- akta.pro secondary industries
- Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE), Nuclear Medicine Imaging Agents & Kits (Cold Kits/Precursors) (HLAIAGAG)
Keywords
Where MH3D is headquartered
LocationHeadquarters
- HQ city
- Commerce Township
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
MH3D business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Alpha-SPECT Mini Hardware Sales: Sale of Alpha-SPECT Mini CZT-based preclinical SPECT imaging systems to CROs, academic institutions, and research organizations. Each unit represents a significant capital sale with potential for follow-on service contracts.
- Service Partnership Revenue: Perceptive Discovery serves as MH3D's exclusive service provider, offering α-Sight imaging services. This creates recurring service revenue through the partnership model while MH3D supplies the hardware platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Alpha-SPECT Mini System - quote-based enterprise pricing |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels5 records
MH3D product offering
Product offeringCore offering
MH3D designs, develops, and sells the Alpha-SPECT Mini, the world's first CZT-based preclinical SPECT imaging system used by contract research organizations and academic medical centers for direct in vivo imaging and quantification of alpha-emitting radiopharmaceuticals in cancer, cardiovascular, and neurodegenerative disease research. The company also enables the α-Sight imaging service via an exclusive service-provider partnership with Perceptive Discovery, and offers an integrated SPECT/CT solution through a partnership with Inviscan.
Product overview
MH3D is a medical device company with a single flagship product: the Alpha-SPECT™ Mini, the world's first CZT-based preclinical SPECT imaging system. The product targets early detection and monitoring of cancer, cardiovascular, and neurodegenerative diseases by enabling direct in vivo imaging of alpha-emitting radiopharmaceuticals. MH3D's commercial strategy includes selling the Alpha-SPECT™ Mini system directly to research institutions and CROs (e.g., Johns Hopkins, Perceptive Discovery, Minerva Imaging), with Perceptive Discovery operating as the exclusive service provider using the system for the α-Sight™ imaging service offering. The system is also offered as an integrated SPECT/CT solution via a partnership with Inviscan's IRIS CT system.
Differentiator
Problem solved
Functional benefit
Brands
- Alpha-SPECT Mini: World's first CZT-based preclinical SPECT imaging system for alpha-emitting radiopharmaceuticals with unmatched energy resolution and sensitivity.
- α-Sight
Products and services
- Alpha-SPECT Mini World's first CZT-based preclinical SPECT imaging system designed for high-sensitivity, high-resolution imaging of alpha-emitting radiopharmaceuticals. Offers dual-field-of-view (standard and focused modes), multi-isotope imaging capability, ~2.5% energy resolution at 140 keV, and sub-2.5 mm spatial resolution. Used by contract research organizations and academic medical centers for biodistribution studies, dosimetry modeling, PK/PD assessment, tumor targeting validation, and longitudinal imaging of theranostic agents in cancer, cardiovascular, and neurodegenerative disease research.
Quantifiable outcome
- High quantification accuracy (~1–10% error across multiple energy peaks)
- +3 more outcomes
Companies that use MH3D
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
MH3D technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature5 records
MH3D partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered major, core and supporting.
- Minerva ImagingmajorMinerva Imaging purchased Alpha-SPECT Mini unit, marking first adoption of MH3D's technology in Europe. Minerva Imaging is a globally recognized CRO specializing in radiopharmaceutical imaging and translational research.
- Perceptive DiscoverycoreStrategic partnership where Perceptive Discovery serves as MH3D's exclusive service provider. The partnership launched α-Sight, a preclinical imaging service for alpha-emitting radiopharmaceuticals using the Alpha-SPECT Mini. Perceptive Discovery provides radiochemistry, imaging, and quantitative image analysis expertise to expand isotope portfolio and decision-making outputs.
- InviscancoreStrategic partnership where Inviscan provides the high-performance IRIS CT system for the SPECT/CT integrated solution offered at Johns Hopkins. The CT modality enables attenuation correction and precise anatomical registration of SPECT images, supporting perfusion imaging, cardiac and pulmonary gating, and vascular imaging applications.
- Scintica InstrumentationmajorScintica Instrumentation serves as a distribution partner for the Alpha-SPECT Mini system, extending MH3D's market reach in the preclinical imaging instrumentation space.
- UK Science and Technology Facilities Council (STFC)supportingUK research council that has provided support for MH3D's development of cutting-edge imaging technology for preclinical and clinical research communities.
- Aspect Systems GmbHsupportingTechnology partner supporting MH3D's development and launch of the Alpha-SPECT Mini imaging platform.
- GeofabricasupportingPartner supporting MH3D's mission to bring cutting-edge imaging technology to preclinical and clinical research communities.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
MH3D competitors and assessment
Company assessmentDirect peers
- Bruker: Bruker's BioSpin preclinical imaging division sells high-field MRI, PET, SPECT, and CT systems to research institutions and CROs, directly competing with MH3D's Alpha-SPECT Mini for the same preclinical imaging budgets.
- MILabs: MILabs manufactures preclinical SPECT, PET, and optical imaging systems (e.g., VECTor, U-SPECT) used in radiopharmaceutical and molecular imaging research — overlapping directly with MH3D's preclinical SPECT value proposition.
- Mediso Medical Imaging Systems: Mediso sells preclinical nanoSPECT/CT and PET/SPECT/CT systems to academic and CRO preclinical imaging labs, competing head-to-head for nuclear-medicine small-animal imaging capital purchases.
- Trifoil Imaging: Trifoil Imaging supplies preclinical Inveon PET/SPECT/CT and optical imaging platforms to translational imaging labs, directly comparable to MH3D's preclinical nuclear imaging offering.
- Spectral Instruments Imaging: Spectral Instruments Imaging builds preclinical optical and gamma cameras/SPECT systems used in small-animal molecular imaging research, overlapping with MH3D's preclinical imaging customer base.
Broad incumbents
- Revvity (formerly PerkinElmer Life Sciences): Revvity offers a broad portfolio of preclinical imaging instruments, radiopharmaceutical reagents, and CRO services, overlapping with MH3D's customer base (CROs and academic researchers) and product category (preclinical imaging).
- GE HealthCare: GE HealthCare is a global leader in clinical and preclinical nuclear medicine imaging (SPECT, SPECT/CT, PET), targeting the same radiopharmaceutical and theranostics research customers as MH3D at much larger scale.
- Siemens Healthineers: Siemens Healthineers provides clinical and research SPECT/PET systems and CZT-based digital detectors in its broader imaging portfolio, anchoring the incumbent landscape that MH3D must differentiate against.
Emerging players
- Inviscan: Inviscan produces high-performance preclinical CT systems (IRIS CT) and is already a technology integration partner of MH3D for SPECT/CT solutions at Johns Hopkins — adjacent preclinical imaging player with overlapping accounts.
Others
- Scintica Instrumentation: Scintica is MH3D's distribution partner for the Alpha-SPECT Mini and also distributes competing preclinical imaging modalities (ultrasound, MRI, optical), giving it a portfolio view of the same buyer base.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
MH3D social profiles
Digital presenceMH3D financial estimates
Financial estimateRevenue estimate
Valuation estimate
MH3D leadership team
Management profileNumber of profiles
Profiles6 records
MH3D funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MH3D M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MH3D
What does MH3D do?
MH3D designs, develops, and sells the Alpha-SPECT Mini, the world's first CZT-based preclinical SPECT imaging system used by contract research organizations and academic medical centers for direct in vivo imaging and quantification of alpha-emitting radiopharmaceuticals in cancer, cardiovascular, and neurodegenerative disease research. The company also enables the α-Sight imaging service via an exclusive service-provider partnership with Perceptive Discovery, and offers an integrated SPECT/CT solution through a partnership with Inviscan.
Is MH3D a public or private company?
MH3D is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was MH3D founded?
MH3D was founded in 2023. It employs 1 to 10 people.
Where is MH3D based?
MH3D is headquartered in Commerce Township, United States, in the North America region.
How does MH3D make money?
Two revenue lines are on record. Alpha-SPECT Mini Hardware Sales are the primary driver. The others are service Partnership Revenue.
Who are MH3D's main competitors?
Direct peers on record are Bruker, MILabs, Mediso Medical Imaging Systems, Trifoil Imaging and Spectral Instruments Imaging. Broad incumbents are Revvity (formerly PerkinElmer Life Sciences), GE HealthCare and Siemens Healthineers. Inviscan is listed as an emerging player. Scintica Instrumentation is listed as an others.
Does MH3D have an API?
No public API is recorded for MH3D.
What industry is MH3D in?
MH3D's product category is Preclinical Nuclear Imaging Systems. Its primary akta.pro industry code is HLAHABAE, Nuclear Medicine & Molecular Imaging (SPECT/PET), with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334510 and its SIC code is 3826.